Candida Auris IgG

If you searched for this test, you probably saw a headline about Candida auris, the drug-resistant hospital yeast spreading through intensive care units. This blood test does not look for the fungus itself. It looks for antibodies. These are proteins your immune system makes after it meets Candida.

That distinction matters. There is no validated blood-antibody test that can diagnose Candida auris or separate it from close relatives. A positive result cannot, on its own, tell you whether you have an active infection or harmless Candida living on your skin or in your gut.

What This Test Measures

IgG is the long-lived antibody class in blood. It can linger for months or years after your immune system learns to recognize something. Plasma cells make IgG. When IgG is aimed at Candida, the result shows immune contact with Candida at some point.

The most carefully studied version of this idea measures antibodies against candidalysin. Candidalysin is a toxin from Candida albicans, the most common Candida species in humans. In a single-center pediatric study with 121 invasive or suspected invasive Candida cases and 105 controls, higher anti-candidalysin IgG helped separate invasive infection from non-invasive comparison groups. This is preliminary, related evidence, not direct Candida auris evidence.

Why This Is Not a Candida auris Diagnosis

Routine anti-Candida antibody tests are not built to name the species. Many Candida species share targets that antibodies recognize, and most blood-antibody work has been developed for Candida albicans or broad Candida detection. That is a serious limit for auris. The clinical problem with this yeast is its drug resistance and its spread in healthcare settings, so species-level identification matters.

Candida auris is identified by growing it in culture, reading its DNA with PCR, or identifying a cultured isolate by MALDI-TOF protein fingerprinting. Serum antibodies do not do that. Two PCR assay studies found about 98 to 100 out of 100 culture-positive samples and correctly cleared about 90 to 100 out of 100 culture-negative samples, with faster turnaround than culture in outbreak settings.

Invasive Candidiasis

This antibody class has been studied most as an add-on test for invasive candidiasis. In invasive candidiasis, Candida has moved beyond surface colonization and into the blood or deep tissue. In the pediatric candidalysin study, anti-candidalysin IgG caught about 80 to 87 out of 100 invasive or probable cases and correctly cleared about 70 to 73 out of 100 controls. On a 0 to 1 separation score, where 1 is perfect and 0.5 is a coin flip, it scored about 0.82 to 0.87.

Invasive candidiasis is not a minor illness. In the same pediatric study, about 16 percent of the invasive or probable group died, compared with about 4 percent of children in the other-infection control group. Those children also had more respiratory, gut, brain, kidney, and heart dysfunction. That does not prove Candida invaded each organ, but it shows the setting this test was being studied in.

Candidemia is Candida in the blood. Antibodies against other Candida proteins have sometimes appeared before blood cultures turn positive in candidemia. That is the appeal of antibody testing. But the early-rise appeal has not held up in tougher testing: in a 2026 study of 342 ICU patients with sepsis at high risk for invasive Candida infection, anti-Candida antibody levels were not clearly elevated in confirmed infection and were confounded by colonization, while antigen tests such as beta-D-glucan and mannan performed better. And it is not species-specific enough for Candida auris.

One finding runs against the obvious reading. In 92 adults with Candida in the blood, people with higher antibodies against two fungal proteins were more likely to survive 30 days. More antibody did not mean worse disease in that study. It looked more like a useful immune response. A flat response can be bad for a different reason: the immune system may be too suppressed to make antibodies.

Why Candida auris Is Different

Candida auris earns attention because it is hard to kill and hard to contain. Most strains resist fluconazole, and some resist multiple antifungal classes. It can persist on skin and healthcare surfaces and spread from patient to patient in intensive care and long-term care settings. Bloodstream infections carry high mortality: one meta-analysis estimated about 45 percent mortality, and a WHO-oriented review found death rates from about 29 to 62 percent across studies.

Most people who carry auris have no symptoms. They carry it on the skin, often in the armpit or groin, and may spread it in healthcare settings. The jump from colonization to infection is driven by illness and medical exposure: central venous catheters, mechanical ventilation, recent antibiotics or antifungals, long intensive care stays, surgery, kidney disease, and diabetes. An antibody level does not capture that risk well. This is why auris surveillance uses skin swabs and molecular testing.

What a Positive or Negative Result Means

A positive antibody result is ambiguous. Healthy people who carry Candida on their skin, in the mouth, or in the gut can have detectable anti-Candida IgG. A positive result does not separate colonization from tissue invasion. In routine mycology labs, about 6 percent of first serum samples were Candida IgG positive, and positivity rose a few-fold when the test was used as a confirmation step rather than a broad screen.

A negative result is not full reassurance. Antibodies take time to rise after a new exposure. Early infection can come before a detectable response. People whose immune systems are suppressed by chemotherapy, transplant drugs, or advanced illness may make less antibody, though anti-Candida IgG assays have still performed reasonably in some neutropenic and transplant patients.

Use an antibody result as context, not a verdict. If you want to know whether Candida auris is present, culture and molecular testing answer that question. This test does not.

Why One Reading Tells You Little

Antibody levels move over time. They rise after exposure and may slowly fall afterward. A paired result can help more than one value when both samples are run by the same lab during a real workup. A clear rise across weeks in someone with fever and recent healthcare exposure carries more weight than a stable low-level result in someone who feels well.

Even then, trends have limits. Candida auris colonization can persist on skin for weeks, months, or longer, and antibody levels have not been validated as a way to show that treatment worked. There is no evidence-based schedule for annual tracking. If the question is Candida auris, culture or PCR settles it better than an antibody level.

What to Do With an Unexpected Result

If your antibody comes back positive and you have signs of a serious infection, such as fever, chills, and low blood pressure after recent hospitalization, do not solve it by repeating the antibody. The next step is blood or sterile-site culture, species-specific PCR or MALDI-TOF identification, and often beta-D-glucan. Beta-D-glucan is a blood marker that can rise with several invasive fungal infections. If Candida auris is confirmed, treatment usually starts with an echinocandin while drug-susceptibility results and the source of infection are sorted out.

If the antibody is positive but you feel well and have no recent healthcare exposure, ordinary colonization is more likely. Useful follow-up is context: your white blood cell count, an inflammation marker such as hs-CRP, and, if you have diabetes, blood sugar control. The pattern matters more than any single antibody number.

When a Result Can Mislead You

• Species blindness: this test cannot distinguish Candida auris from Candida albicans, Candida glabrata, or other Candida species, so a positive result never confirms auris.
• A suppressed immune system: chemotherapy, transplant medication, or advanced illness can blunt antibody production, so a low result may be falsely reassuring, though these assays have still performed reasonably in some immunosuppressed patients.
• Colonization without disease: harmless Candida on the skin, mouth, or gut can raise antibodies without tissue invasion.
• Early timing: antibodies take time to build, so a sample drawn soon after a new exposure can read negative before the response has developed.